Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
...
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT01916265
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany
Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Registration Number
- NCT01828125
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 6
- Registration Number
- NCT01795235
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Clinique Ovo
- Registration Number
- NCT01674283
- Locations
- 🇨🇦
Clinique Ovo, Montréal, Quebec, Canada
Study of LY2409021 in Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01640834
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
Physiologic Response to Glucagon at Varying Insulin Levels
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Legacy Health System
- Target Recruit Count
- 11
- Registration Number
- NCT01483651
- Locations
- 🇺🇸
Legacy Health System, Portland, Oregon, United States
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
- Conditions
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01300260
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 9
- Registration Number
- NCT01155206
- Locations
- 🇨🇦
University Health Network, Toronto General Hospital, Toronto,, Ontario, Canada
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT00823940
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
To Evaluate the Response to Glucagon During Hypoglycemia
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2009-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00817271
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.